CAS 677007-74-8

Avatrombopag Meleate

CAS : 677007-74-8

Formule : C₃₃H₃₈Cl₂N₆O₇S₂

Degré de pureté : 98%

Masse moléculaire : 765.7268

Ref: IN-DA01V5CK

1-(3-Chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid maleate

CAS : 677007-74-8

1-(3-Chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid maleate

Degré de pureté : 98%

Masse moléculaire : 765.74g/mol

Ref: 54-OR1067426

Avatrombopag maleate

CAS : 677007-74-8

Avatrombopag (AKR-501/E5501) is an oral TPO receptor agonist for thrombocytopenia treatment, approved in 2018.

Formule : C₃₃H₃₈Cl₂N₆O₇S₂

Couleur et forme : Solid

Masse moléculaire : 765.72

Ref: TM-T68888

Avatrombopag Maleate

Produit contrôlé

CAS : 677007-74-8

Formule : C₂₉H₃₄Cl₂N₆O₃S₂·C₄H₄O₄

Couleur et forme : Neat

Masse moléculaire : 765.72

Ref: TR-A819920

Avatrombopag maleate

CAS : 677007-74-8

Avatrombopag maleate is a small molecule that activates platelets by binding to the beta-granule protein receptor. This drug has been shown to improve blood clotting and lower the need for blood transfusions in patients with thrombocytopenia, which is a condition where there are fewer than normal numbers of platelets in the blood. Avatrombopag maleate has also been shown to reduce brain infarct volume after stroke, suggesting that it may be useful for treating ischemic stroke.

Formule : C₃₃H₃₈Cl₂N₆O₇S₂

Degré de pureté : Min. 95%

Masse moléculaire : 765.7 g/mol

Ref: 3D-CCB00774